Navigation Links
Leaders in the Study of Allosteric Modulation to Discuss Latest Research at Allosteric and Orthosteric Modulator Congress
Date:11/4/2009

Arrowhead’s 2010 Allosteric and Orthosteric Modulator Congress, scheduled to take place in Philadelphia, PA on January 25 and January 26, 2010, will highlight key developments in the field of allosteric and orthosteric modulator drug discovery and clinical development.

Minneapolis, Minnesota (PRWEB) November 4, 2009 -- Arrowhead’s 2010 Allosteric and Orthosteric Modulator Congress, scheduled to take place in Philadelphia, PA on January 25 and January 26, 2010, will highlight key developments in the field of allosteric and orthosteric modulator drug discovery and clinical development.

Our speakers will discuss key developments in the field, including the challenges facing researchers, the opportunities for pharma and recent successes in the field.

Allosteric modulators are on the cutting edge of small molecule drug discovery, and therefore, are generating a great deal of excitement among researchers. This potential stems from their ability to offer greater selectivity and better modulatory control at disease mediating receptors. Since orthosteric modulators need to compete with natural ligands, they require higher doses, raising safety issues. Allosteric modulators do not compete and may therefore be effective at lower, safer doses.

Arrowhead’s 2010 Allosteric and Orthosteric Modulator Congress will highlight many key developments in the field. Conference attendees will come away with a better understanding of the following topics:

- Allosteric modulators of GPCRs as a novel approach to treatment of CNS disorders
- Dualsteric GPCR testing
- Allosteric modulation of GPCRs and transporters for the treatment of depression
- Structure-function approaches to understanding allosteric modulation of GPCRs
- Allosteric modulation of purine receptors
- Discovery of small molecule GPCR modulators
- Muscarinic receptors/GPCRs in endocrine and central nervous systems
- Morpheeins as a new pathway for allosteric drug discovery
- Allosteric proteins and the concept of allosteric modulators

Speakers at this year’s congress include:

- P. Jeffrey Conn, Ph.D., Director, Vanderbilt Program in Drug Discovery, Lee E. Limbird Professor of Pharmacology, Vanderbilt University Medical Center
- Patrick M. Sexton, Ph.D., Professor of Pharmacology, Drug Discovery Biology Laboratory, Monash Institute of Pharmaceutical Sciences & Department of Pharmacology, Monash University
- Jean-Pierre Changeux, Ph.D., Professor, Institut Pasteur
- Charlotte Keywood, MD, Chief Medical Officer, Addex Pharmaceuticals
- Connie Sanchez, Ph.D., Vice President Neuroscience, Lundbeck Research USA
- Prof. Dr. Klaus Mohr, Chairman, Pharmacology and Toxicology Section, Institute of Pharmacy, University of Bonn
Kenneth A. Jacobson, Ph.D., Acting Chief, Laboratory of Bioorganic Chemistry, National Institutes of Health
Robert Lütjens, Ph.D., Head of Core Biology, Addex Pharmaceuticals
Marlene A. Jacobson, Ph.D., Senior Investigator, Merck Research Labs
Jurgen Wess, Ph.D., Chief, Molecular Signaling Section, National Institutes of Health, NIDDK

For more information about this conference, please visit www.allostericmodulatorcongress.com/ or call 1-312-244-3703.

# # #

Read the full story at http://www.prweb.com/releases/2009/11/prweb3154864.htm.


'/>"/>
Source: PRWeb
Copyright©2009 Vocus, Inc.
All rights reserved

Related medicine news :

1. Yakima Health Care Leader Tapped for Leadership Post at National Association
2. Tennessee Faith Leaders Call on Reps. Gordon & Blackburn to Co-sponsor Legislation to Protect Kids from Tobacco
3. National Pharmaceutical Council Announces New Strategic Focus, Search for New Leadership
4. TriWest Creates First-of-its-Kind Partnership to Offer Military Leaders With Grief Support Program
5. Patent Reform Legislation Threatens Americas Leadership in Medical Technology Innovation
6. Dow Jones Sustainability Index Again Recognizes Abbott for Continued Leadership in Business, Environmental and Social Performance
7. Hooper Holmes Launches Health & Wellness Division at 2007 Disease Management Leadership Forum and Integrated Care Summit
8. CEO Addresses Tennessee Business Leaders About Developing Pandemic and Business Continuity Plans
9. Blue Care Network of Michigan Earns National Leadership Award for Chronic Disease Management
10. Schooner Healthcare Services, LLC Announces New Leadership Team
11. U.S. Reps. Oberstar and Walz Discuss DM&E Railroad Expansion With Rochester, Minn. Leaders
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/24/2017)... ... 24, 2017 , ... “End Time GPS”: a dauntless and enlightened study ... Time GPS” is the creation of published author, Wesley Gerboth, a World War II ... and space-vehicle projects. Now, at age ninety-one, he shares the Wisdom God bestowed upon ...
(Date:3/24/2017)... ... , ... “The Adventures of Joey, The Dog Who Barks at Puddles”: a ... to the fullest, as God intended. “The Adventures of Joey, The Dog Who Barks ... pursuing her passion for writing, especially about truth and human behavior. , Published by ...
(Date:3/23/2017)... ... ... The physicians of KSF Orthopaedic Center PA are proud to announce the ... located at 2255 E. Mossy Oaks Rd., Suite 440, Spring, Texas 77389 inside the ... living in the north Houston area (The Woodlands, Conroe, Magnolia, Kingwood, Humble) with an ...
(Date:3/23/2017)... (PRWEB) , ... March 23, 2017 , ... ... Oklahoma City Convention Center at 10 North Broadway Avenue, will be an educational ... of relevant, practical instruction in the management of chronic pain. , Oklahoma is ...
(Date:3/23/2017)... ... ... of adults are unaware of the dangers that infectious bacteria play in mouth disease, while ... a day that dentists recommend. The ramifications of improper oral upkeep go far beyond bad ... 164 million hours of work each year due to dental issues. That is why Mediaplanet ...
Breaking Medicine News(10 mins):
(Date:3/24/2017)... , March 23, 2017  Provectus Biopharmaceuticals, Inc. ... "Company"), a clinical-stage oncology and dermatology biopharmaceutical company, ... Financing Commitment Term Sheet (the "Definitive Financing") it ... of the Company,s stockholders, who are referred to ... a Form 8-K filed with the Securities and ...
(Date:3/23/2017)... The key factors driving the growth ... accelerating economic growth and increasing healthcare expenditure. Some of the ... expectancy of ESRD patients, rising demand for home PD treatment ... of the market is hindered by high treatment costs and ... ...
(Date:3/23/2017)... -- As a result of diagnostic technology increasing ... allergic diseases, cutting edge developments in targeted drugs ... in which pharmaceutical and biotech companies are addressing ... both a high quality meeting and a platform ... research scholars and doctors. The event will also ...
Breaking Medicine Technology: